Mostrando 10 resultados de: 20
Publisher
Cancer Biology and Therapy(4)
Bionatura(2)
Immunotherapy(2)
Cancer Biotherapy and Radiopharmaceuticals(1)
Clinical and Translational Immunology(1)
Área temáticas
Enfermedades(20)
Farmacología y terapéutica(10)
Medicina y salud(8)
Microorganismos, hongos y algas(3)
Problemas sociales y servicios a grupos(2)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(20)
ODS 10: Reducción de las desigualdades(18)
ODS 17: Alianzas para lograr los objetivos(16)
ODS 9: Industria, innovación e infraestructura(3)
ODS 1: Fin de la pobreza(1)
Origen
scopus(20)
A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer
ArticleAbstract: Nimotuzumab is a humanized IgG1 monoclonal antibody against the EGFR extracellular domain that has bPalabras claves:Advanced cervical cancer, eGFR, Monoclonal antibody, nimotuzumab, Pilot studyAutores:Astudillo H., Avila S., Bazán B., Blanca Bazán, Bojalil R., Cetina L., Charco E., Coronel J., Crombet-Ramos T., Dueñas-Gonzãlez A., Jiménez-Lima R., Lucely Cetina, Ramos M., Zapata S.Fuentes:scopusTreatment of COVID-19 patients with the anti-CD6 antibody itolizumab
ArticleAbstract: Objectives: COVID-19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on maturPalabras claves:CD6, covid-19, Cytokine release syndrome, Itolizumab, Monoclonal antibody, Sars-cov2Autores:Arencibia M., Betancourt J., Caballero A., Cabrera L., Castillo U., Cepeda M., Crombet-Ramos T., Danay Saavedra, Despaigne R.E., Diaz H., Domecq M., Escalona A., Estevez D., Filgueira L.M., García Y., Geydi Lorenzo, Hidalgo C.J., Leon K., Lorenzo G., Lorenzo P., Luaces P.L.o., Martinez A., Mazorra Z., Meriño E., Ortega L.M., Ramírez A., Ramos M., Saavedra Hernández D., Sánchez L., Sánchez N., Valenzuela-Silva C.M., Yanelda GarcíaFuentes:scopusTreatment of malignant, non-resectable, epithelial origin esophageal tumors with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy
ArticleAbstract: Overexpression of epidermal growth factor receptor in esophageal cancer is associated with poor progPalabras claves:Chemorariotherapy, Esophageal cancer, Humanized monoclonal, nimotuzumabAutores:Albuerne Y.A., Alert J., Alvarez E.S., Callejo I.P., Crombet-Ramos T., De La Vega H.A., Gonzalez C.E.V., Gonzalez Y.S., Hernadez I.M., Lazo N.G., Luaces P.L.o., Martell J.A.n., Mayté Lima Pérez, Moreno B.P., Perez M.L., Ramos M., Ramos-Suzarte M., Ruiz-Garcia E.B., Soriano J.L., Yanela Santiesteban GonzalezFuentes:scopusSystemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumab
ArticleAbstract: Nimotuzumab (h-R3) is a humanized anti-epidermal growth factor receptor monoclonal antibody (mAb) rePalabras claves:animal model, CETUXIMAB, Epidermal growth factor receptor, General toxicity, H-R3, Monkeys, nimotuzumab, Skin toxicityAutores:Arteaga M.E., Aylen Pérez, Ballester-Labrada A., Baro F., Boleda M., Casacó Parada A.R., Charro L., Crombet-Ramos T., Fuentes D., García M., González B., González C., Hernández O., Ledón N., Macías A.E., Morales Y., Orphee R., Pardo B., Pérez A., Ramos M., Rodríguez V., Rodriquez L., Subirós N., Viña L.Fuentes:scopusUse of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19
ArticleAbstract: Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a recent outbreaPalabras claves:Autores:Caballero A., Calderón N.A., Cepeda M., Crombet-Ramos T., Danay Saavedra, Diáz Y., Estevez D., Hidalgo C.J., La O Y., Leon K., Lorenzo G., Luaces P.L.o., Martín Y., Mazorra Z., Oyarzábal J.P.A., Pérez Y., Ramos M., Ramos-Suzarte M., Saavedra Hernández D., Santiago W., Valenzuela-Silva C.M., Viñet O.Fuentes:scopusUse of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients
ArticleAbstract: Purpose: To evaluate safety and preliminary efficacy of the humanized anti-epidermal growth factor rPalabras claves:Autores:Alvarez D., Crombet-Ramos T., Cruz T., Del Castillo R., Fernández E., Figueredo R., Iznaga-Escobar N., Koropatnick J., Lage Davila A., Leonard I., Mon R., Osorio M., Pérez R., Ramos M., Renginfo E., Roca C., Rolando Pérez, Torres O.Fuentes:scopusAn anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: Report of three cases
ArticleAbstract: In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the diPalabras claves:CD6 molecule, coronavirus 2, covid-19, Cytokine release syndrome, IL-6, Itolizumab, Monoclonal antibody, SARS-CoV-2Autores:Añe-Kouri A.L., Berrio J., Caballero A., Caballero J.A., Cepeda M., Cervantes J.B., Crombet-Ramos T., Danay Saavedra, Figueredo C., Filgueira L.M., Herrera C., Leon K., Lorenzo G., Lovelle O.A., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N.Fuentes:scopusAn anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
ArticleAbstract: Background: Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around thePalabras claves:covid-19, Cytokine release syndrome, IL-6, ItolizumabAutores:Añe-Kouri A.L., Betancourt J., Caballero A., Cepeda M., Chávez E., Crombet-Ramos T., Danay Saavedra, Filgueira L.M., Geydi Lorenzo, Herrera C., Hidalgo C.J., Leon K., Lorenzo G., Manso L., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Valenzuela-Silva C.M.Fuentes:scopusEvaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials
ArticleAbstract: Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: hPalabras claves:Epidermal growth factor receptor, Head and neck tumors, Humanized monoclonal antibody, nimotuzumabAutores:Aliuska Frías, Carmen Elena Viada, Crombet-Ramos T., García L., Lázara García, Mabel Álvarez, Macías A.E., Mestre B.F., Osorio M., Pérez Ruiz L., Ramos M., Robaina M., Santiesteban Y., Vega A.M.Fuentes:scopusEvaluation of quality of life in patients with non-small cell lung cancer treated with CIMAvaxEGF® vaccine
ArticleAbstract: This report corresponds to quality of life analysis of patient with non-small cell lung cancer incluPalabras claves:Cancer Vaccines, clinical trials, Non-small cell lung cancer, Quality of Life, surveys and questionnairesAutores:Álvarez-Cardona M., Carmen Elena Viada, Crombet-Ramos T., Frías-Blanco A., Lorenzo G., Lorenzo-Monteagudo G., Neninger-Vinagera E., Ramos M., Ramos-Suzarte M., Rodríguez P.C.Fuentes:scopus